Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.81 |
| ▸ | CNR1 | P21554 | 6/20 | 0.74 |
| ▸ | NPC1 | O15118 | 3/20 | 0.73 |
| ▸ | RAB9A | P51151 | 3/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
| ▸ | FPR2 | P25090 | 1/20 | 0.68 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.68 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.68 |
| ▸ | CA2 | P00918 | 2/20 | 0.66 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.66 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | MAOB | P27338 | 1/20 | 0.63 |
| ▸ | CA12 | O43570 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | CA9 | Q16790 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21045450 | 0.90 | KMT2A (1.00) | KMT2ACNR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4606056 | 0.89 | EPHX1 (0.81) | KMT2ACNR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19472643 | 0.86 | CNR1 (0.76) | KMT2ACNR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22834268 | 0.85 | CNR1 (1.00) | CNR1NPC1RAB9ASMN1; SMN2FPR2 | |
| SCHEMBL4638306 | 0.85 | CNR1 (0.74) | KMT2ACNR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16946646 | 0.85 | CNR1 (0.74) | KMT2ACNR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4894746 | 0.84 | CNR1 (1.00) | KMT2ACNR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10192078 | 0.84 | ALDH1A1 (0.83) | KMT2ACNR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4897395 | 0.84 | CNR1 (0.74) | KMT2ACNR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5516178 | 0.84 | CNR1 (0.73) | KMT2ACNR1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009477-A1 | Arylalkyl Ureas As Cb1 Antagonists | NEUROGEN CORPORATION (US) | 2008-01-10 | — | — | US | disclosed |
| US-20080009477-A1 | Arylalkyl Ureas As Cb1 Antagonists | NEUROGEN CORPORATION (US) | 2008-01-10 | — | — | US | disclosed |
| US-20080009477-A1 | Arylalkyl Ureas As Cb1 Antagonists | NEUROGEN CORPORATION (US) | 2008-01-10 | — | — | US | disclosed |
| EP-0720601-B1 | GASTRIN AND CCK RECEPTOR LIGANDS | BLACK JAMES FOUNDATION (GB) | 2000-10-25 | — | — | EP | disclosed |
| US-5919829-A | Gastrin and cck receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 1999-07-06 | — | — | US | disclosed |
| US-5795907-A | Gastin and CCK receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 1998-08-18 | — | — | US | disclosed |
| EP-0720601-A1 | GASTRIN AND CCK RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 1996-07-10 | — | — | EP | disclosed |
| WO-1995004720-A2 | GASTRIN AND CCK RECEPTOR LIGANDS | BLACK JAMES FOUNDATION (GB) | 1995-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009477-A1 | Arylalkyl Ureas As Cb1 Antagonists | CNR1, CNR2, GPR119 | KMT2A 1756/4885CNR1 1/4885NPC1 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.